Personalized Management of Bone and Mineral Disorders and Precision Medicine in End-Stage Kidney Disease.
Personalized Management of Bone and Mineral Disorders and Precision Medicine in End-Stage Kidney Disease.
复制标题
DOI：
10.1016/j.semnephrol.2018.05.009
复制
发表时间：
2018-07
影响因子：
3.3
通讯作者：
Kendrick J
中科院分区：
文献类型：
--
作者：
Jovanovich A;Kendrick J
Chronic kidney disease mineral bone disorder (CKD-MBD) is common in end-stage renal disease and is associated with an increased risk of cardiovascular morbidity and mortality. Mainstays of treatment include decreasing serum phosphorus level toward the normal range with dietary interventions and phosphate binders and treating increased parathyroid hormone levels with activated vitamin D and/or calcimimetics. There is significant variation in serum levels of mineral metabolism markers, intestinal absorption of phosphorus, and therapeutic response among individual patients and subgroups of patients with end-stage renal disease. This variation may be partly explained by polymorphisms in genes associated with calcium and phosphorus homeostasis such as the calcium-sensing receptor gene, the vitamin D–binding receptor gene, and genes associated with vascular calcification. In this review, we discuss how personalized medicine may be used for the management of CKD-MBD and how it ultimately may lead to improved clinical outcomes. Although genetic variants may seem attractive targets to tailor CKD-MBD therapy, complete understanding of how these polymorphisms function and their clinical utility and applicability to personalized medicine need to be determined.
登录
查看更多内容
影响因子：
168.9
作者：
Cole, DEC;Peltekova, VD;Hendy, GN
通讯作者：
Hendy, GN
影响因子：
3.7
作者：
Berchtold L;Ponte B;Moll S;Hadaya K;Seyde O;Bachtler M;Vallée JP;Martin PY;Pasch A;de Seigneux S
通讯作者：
de Seigneux S
影响因子：
1.6
作者：
Daugirdas, John T.
通讯作者：
Daugirdas, John T.
影响因子：
13.2
作者：
Di Iorio, Biagio;Molony, Donald;Bellasi, Antonio
通讯作者：
Bellasi, Antonio
影响因子：
19.6
作者：
Almaden, Y;Felsenfeld, AJ;Canalejo, A
通讯作者：
Canalejo, A